Gagandeep Sukhija
Gagan is a rheumatology trainee at St George’s Hospital, NHS Foundation Trust, London. His research and clinical interests include lupus, vasculitis and interstitial lung disease (ILD), alongside medical education and service improvement. He has presented work on global disparities in therapies and remains committed to improving access and equity in rheumatology care. He is a member of the British Society for Rheumatology (BSR) and serves on the EMEUNET Social Media Sub-Committee.
| Poster 0333 | Sunday, 26.10.25 10:30–12:30 Abstract Session: (0306–0336) Osteoarthritis – Clinical Poster I Presenting author: M Abdelsalam (Egypt) Title: Diagnostic Test Accuracy of Artificial Intelligence in Early Diagnosis of Osteoarthritis: A Systematic Review and Meta-Analysis of 45,588 Knees.  This interesting study assessed 14 studies (45,588 knee radiographs) and found AI algorithms classify Kellgren–Lawrence grades with consistently high specificity and good sensitivity across grades, supporting AI as a helpful aid for earlier KOA diagnosis. |
| Poster 0333 | Sunday, 26.10.25 10:30–12:30 Abstract Session: (0306–0336) Osteoarthritis – Clinical Poster I Presenting author: M Abdelsalam (Egypt) Title: Diagnostic Test Accuracy of Artificial Intelligence in Early Diagnosis of Osteoarthritis: A Systematic Review and Meta-Analysis of 45,588 Knees. This interesting study assessed 14 studies (45,588 knee radiographs) and found AI algorithms classify Kellgren–Lawrence grades with consistently high specificity and good sensitivity across grades, supporting AI as a helpful aid for earlier KOA diagnosis. |
| Poster 0342 | Sunday, 26.10.25 10:30–12:30 Abstract Session: (0337–0356) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster I Presenting author: E Wiebe (Germany) Title: Backscatter Ultrasound, Reference-Point Indentation and Bone Mineral Density in Discriminating Prevalent Fragility Fractures in Inflammatory Rheumatic Diseases: A Pilot Study This interesting study assessed Cortical Backscatter ultrasound, reference-point indentation (BMSi), and DXA in 97 iRMD patients and found CortBS discriminated fractures comparably to DXA overall and outperformed DXA/BMSi for vertebral fractures, suggesting a radiation-free tool that captures cortical microstructure for fracture risk assessment. |
| Poster 0339 | Sunday, 26.10.25 10:30–12:30 Abstract Session: (0337–0356) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster I Presenting author: A Shahane (USA) Title: Evaluating Discordance between Bilateral Hip Bone Density Measurements in Individuals with Low Bone Mass This interesting study assessed This interesting study assessed bilateral vs unilateral hip DXA in adults ≥50 and found that 7% were reclassified into osteoporosis when both hips were measured (with ~19% showing ≥0.5 T-score side-to-side difference), suggesting unilateral hip DXA may miss treatable osteoporosis. |
| Oral Presentation 1737 | Tuesday, 28.10.25 10:45–11:00 Abstract Session: Osteoarthritis & Joint Biology – Basic Science (1734–1739) Presenting author: L Giancotti (Italy) Title: CR10049, the first intra-articular Src family kinase inhibitor as a long-acting symptom- and disease-modifying drug for the inflammatory OA phenotype. This interesting study assessed a multi-kinase, intra-articular Src-family inhibitor (CR10049) in long-duration MIA rat and ACLT rabbit OA models and found sustained pain reduction to day 91 and improved joint structure (cartilage, osteophytes, subchondral bone) for months, with supportive acute toxicology—positioning CR10049 as a possible long-acting candidate for inflammatory OA. |
| Oral Presentation 2596 | Tuesday, 28.10.25 14:15–14:30 Abstract Session: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (2591–2596) Presenting author: S Sarfraz (USA) Title: Predicting Osteoporosis Using Routine Clinical Data: A Machine Learning Approach This interesting study assessed 2083 participants from NHANES 2021–2022 cohort using only non-imaging clinical and lifestyle variables. The study showed a random forest model could identify DXA-defined osteoporosis with excellent performance (AUC 0.99; sensitivity ~82%; specificity 100%), outperforming logistic regression and suggesting a low-cost triage tool where DXA access is limited. |
| Oral Presentation 2592 | Tuesday, 28.10.25 13:15–13:30 Abstract Session: Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science (2591–2596) Presenting author: G Adami (Italy) Title: Romosozumab and Denosumab Combination Therapy in Postmenopausal Osteoporosis This interesting study assessed a 36-month, quasi-experimental cohort where adding romosozumab to ongoing denosumab (n=25) was compared with continuing denosumab alone (n=25), showing a greater lumbar-spine BMD gain (≈+11.6% vs +8.3%) and a rise in P1NP, indicating denosumab did not blunt romosozumab’s anabolic response and supporting this strategy for patients failing denosumab. |
| Oral Presentation 2626 | Tuesday, 28.10.25 16:15–16:30 Abstract Session: Osteoarthritis – Clinical (2621–2626) Presenting author: Y Yazici (USA) Title: Lorecivivint Delayed Time to Pain and Function Worsening Compared to Placebo: Evaluation of Knee OA Symptom Progression Outcomes in a Phase 3 Trial (OA-07) This interesting study assessed post-hoc outcomes from a phase 3, single-injection trial and found lorecivivint significantly reduced the odds and delayed time to progression in WOMAC Pain and Function versus placebo (e.g., OR ~1.8–1.9 for less progression), with similar benefits seen after placebo patients crossed over to lorecivivint. |